BEND, Ore.--()--Agere Pharmaceuticals, Inc., a leading oral bioavailability contract research and manufacturing organization (CRO/CMO), will present at IQPC’s “7th Annual Improving Solubility” Conference in Philadelphia.
“Amorphous Solid Dispersions: Toward a Predictable Science”
CONFERENCE: IQPC 7th Annual Improving Solubility Conference February 26-28, 2013 Philadelphia, PA
WHAT: Presentation: “Amorphous Solid Dispersions: Toward a Predictable Science”
- A new approach to make formulation a rigorous, predictable science
- A proposal for automation enabled by a physical chemistry foundation
- Agere’s progress to date toward the goal
WHO: Marshall Crew, President and CEO, Agere
For more information, or to set up a private meeting, please contact us at firstname.lastname@example.org.
Agere is a leading CRO/CMO focused on improving the oral bioavailability of insoluble APIs. The company supports clients from formulation design and development through cGMP manufacturing for Phase I through Phase IIb clinical trials. Agere is expert in solid dispersion techniques including spray drying and hot melt extrusion (HME), and in a broad selection of solid dosage forms. All services are delivered on a fee-for-service basis, and every project the company undertakes is customized to serve each individual client’s requirements. Agere is located in Bend, OR. For information: www.agerepharma.com.